3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER_GOV
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
NET
1
Endocrine
1
Conditions
Breast Neoplasms
23
Ovarian Neoplasms
18
Neoplasm Metastasis
12
Triple Negative Breast Neoplasms
9
Prostatic Neoplasms
9
Pancreatic Neoplasms
8
Neoplasms
8
Fallopian Tube Neoplasms
6
Squamous Cell Carcinoma of Head and Neck
4
Advanced Solid Tumors
4
Small Cell Lung Carcinoma
3
Recurrence
3
Head and Neck Neoplasms
3
Endometrial Neoplasms
3
Carcinoma, Squamous Cell
3
Solid Tumors
2
Sarcoma
2
Neuroendocrine Tumors
2
Lymphoma
2
Lung Neoplasms
2
Hodgkin Disease
2
Fanconi Anemia, Complementation Group D1
2
Carcinoma, Non-Small-Cell Lung
2
Advanced Solid Tumours
2
Advanced Solid Tumor
2
Advanced Cancer
2
Triple Negative Metastatic Breast Cancer
1
Thymoma
1
Thrombocytosis
1
Solid Tumor
1
Interventions
Cisplatin
11
Pemetrexed
10
pembrolizumab
9
Nivolumab
3
LMB-100
3
budigalimab
2
belinostat
2
amatuximab
2
Paclitaxel
2
Docetaxel
2
Dexamethasone
2
Cyclophosphamide
2
Carboplatin
2
Calcium Dobesilate
2
venetoclax
1
trametinib
1
tislelizumab
1
tazemetostat
1
talazoparib
1
spartalizumab
1
sodium thiosulfate
1
sargramostim
1
ruxolitinib
1
rovalpituzumab tesirine
1
olaparib
1
obinutuzumab
1
naptumomab estafenatox
1
irinotecan sucrosofate
1
fludarabine
1
enzalutamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Mesothelioma
×
olaparib
×
Clear all
NCT04375267
2026-04-14
LuPARP
Vastra Gotaland Region
Phase 1
Completed
18 enrolled